Cargando…

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

BACKGROUND: The purpose of this phase Ib clinical trial was to determine the maximum tolerated dose (MTD) of PR-104 a bioreductive pre-prodrug given in combination with gemcitabine or docetaxel in patients with advanced solid tumours. METHODS: PR-104 was administered as a one-hour intravenous infusi...

Descripción completa

Detalles Bibliográficos
Autores principales:	McKeage, Mark J, Jameson, Michael B, Ramanathan, Ramesh K, Rajendran, Joseph, Gu, Yongchuan, Wilson, William R, Melink, Teresa J, Tchekmedyian, N Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495895/ https://www.ncbi.nlm.nih.gov/pubmed/23098625 http://dx.doi.org/10.1186/1471-2407-12-496

Ejemplares similares

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients
por: McKeage, Mark J, et al.
Publicado: (2011)

Sulforaphane Preconditioning Sensitizes Human Colon Cancer Cells towards the Bioreductive Anticancer Prodrug PR-104A
por: Erzinger, Melanie M., et al.
Publicado: (2016)

Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3
por: Abbattista, Maria R., et al.
Publicado: (2021)

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
por: Guise, Christopher P., et al.
Publicado: (2014)

Antibody-Based Imaging of Bioreductive Prodrug Release in Hypoxia
por: Tosun, Çağla, et al.
Publicado: (2023)

The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104
por: Foehrenbacher, Annika, et al.
Publicado: (2013)

The dinitrobenzamide mustard prodrugs, PR-104A and SN27686, for use in a novel MNDEPT cancer prodrug therapy approach
por: Ball, Patrick, et al.
Publicado: (2023)

Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104
por: Benito, Juliana, et al.
Publicado: (2011)

Bioreductive drugs and the selective induction of tumour hypoxia.
por: Bremner, J. C., et al.
Publicado: (1990)

DNA Adduct Profiles Predict in Vitro Cell Viability after Treatment with the Experimental Anticancer Prodrug PR104A
por: Stornetta, Alessia, et al.
Publicado: (2017)

Recent Development of Prodrugs of Gemcitabine
por: Pandit, Bhoomika, et al.
Publicado: (2022)

Enhanced bioreduction-responsive diselenide-based dimeric prodrug nanoparticles for triple negative breast cancer therapy
por: He, Xi, et al.
Publicado: (2018)

Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies.
por: Wang, J., et al.
Publicado: (1993)

Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours
por: Hussein, D, et al.
Publicado: (2009)

Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug
por: Rais, Rana, et al.
Publicado: (2022)

The anti-tumor efficacy of 3-(2-Nitrophenyl) propionic acid-paclitaxel (NPPA-PTX): a novel paclitaxel bioreductive prodrug
por: Song, Ping, et al.
Publicado: (2016)

Cyclic Dichalcogenides Extend the Reach of Bioreductive Prodrugs to Harness Thiol/Disulfide Oxidoreductases: Applications to seco-Duocarmycins Targeting the Thioredoxin System
por: Felber, Jan G., et al.
Publicado: (2023)

Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine
por: Friery, O P, et al.
Publicado: (2000)

Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase.
por: Butler, S. A., et al.
Publicado: (1997)

Development and Bioorthogonal Activation of Palladium-Labile Prodrugs of Gemcitabine
por: Weiss, Jason T., et al.
Publicado: (2014)

Delivery of Gemcitabine Prodrugs Employing Mesoporous Silica Nanoparticles
por: Malfanti, Alessio, et al.
Publicado: (2016)

Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent
por: Patterson, L H, et al.
Publicado: (2000)

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
por: Lockhart, A Craig, et al.
Publicado: (2018)

Docetaxel/gemcitabine: Various toxicities: 4 case reports
Publicado: (2021)

Self-delivering prodrug-nanoassemblies fabricated by disulfide bond bridged oleate prodrug of docetaxel for breast cancer therapy
por: Zhang, Shenwu, et al.
Publicado: (2017)

Bioreduction: the biological activity, characterization, and synthesis of silver
por: KORKMAZ, Nesrin
Publicado: (2020)

Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine
por: Tsume, Yasuhiro, et al.
Publicado: (2017)

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours
por: Attard, G, et al.
Publicado: (2007)

Antitumor activity of the bioreductive prodrug 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) on MDA-MB-231 cells: in vitro and in vivo
por: Duan, Xiao-Chuan, et al.
Publicado: (2018)

Mitozolomide-induced sensitisation of mammalian cells in vitro to radiation.
por: McKeage, M. J., et al.
Publicado: (1989)

Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA
por: McKeage, Kate, et al.
Publicado: (2018)

Correction to: Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA
por: McKeage, Kate, et al.
Publicado: (2018)

Ginkgo biloba extract EGb 761(®) in the symptomatic treatment of mild-to-moderate dementia: a profile of its use
por: McKeage, Kate, et al.
Publicado: (2018)

SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer
por: Vasey, P A, et al.
Publicado: (2006)

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
por: Liu, Zhiyong, et al.
Publicado: (2022)

Radiosensitization of hypoxic tumour cells by S-nitroso-N-acetylpenicillamine implicates a bioreductive mechanism of nitric oxide generation
por: Janssens, M Y, et al.
Publicado: (1999)

Stereoselective Bioreduction of α-diazo-β-keto Esters
por: González-Granda, Sergio, et al.
Publicado: (2020)

Metagenomic ene-reductases for the bioreduction of sterically challenging enones
por: Dobrijevic, Dragana, et al.
Publicado: (2019)

Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
por: Joensuu, H., et al.
Publicado: (2010)

Induction of DT-diaphorase by 1,2-dithiole-3-thiones in human tumour and normal cells and effect on anti-tumour activity of bioreductive agents.
por: Doherty, G. P., et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_9a2513mpbbbk1r4n1t1l2hf605